In the BioHarmony Drug Report Database
Tagraxofusp-erzs
Elzonris (tagraxofusp) is a protein pharmaceutical. Tagraxofusp was first approved as Elzonris on 2018-12-21. It is used to treat malignant histiocytic disorders in the USA. It has been approved in Europe to treat lymphoma.
Trade Name
|
Elzonris |
|---|---|
Common Name
|
tagraxofusp |
ChEMBL ID
|
CHEMBL4297573 |
Indication
|
lymphoma, malignant histiocytic disorders |
Drug Class
|
Fusion proteins |
Image (chem structure or protein)
